Dassault Systemes vs Manhattan Associates: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dassault Systemes SE (DSY.PA)

Q3 202616 Jul – 18 Aug 2026

▲4

Dassault expands life-sciences AI with ArisGlobal deal and new AI tools

ArisGlobal acquisition expands life-sciences AI platform Dassault agreed to buy ArisGlobal, a drug-safety and compliance software firm, for about $1.8 billion plus up to $200 million in milestone payments. ArisGlobal serves over 200 customers and half of the top 50 biopharma companies, deepening Dassault's life-sciences reach and adding recurring revenue.
This is the period's biggest strategic move, directly expanding a key growth business and supporting future revenue.
Q2 results solid, full-year targets confirmed Dassault reported Q2 revenue up 4% at constant currencies to €1.56 billion, with subscription revenue up 8% and cloud and 3DEXPERIENCE software each up 14%. Operating margin was 30.0% and earnings per share rose 8%. Management confirmed full-year targets, signaling steady demand.
Solid results and confirmed guidance underpin investor confidence in the company's core business.
New AI products launched across Medidata and 3DEXPERIENCE Medidata launched Medidata Plus, an AI layer for clinical trials, with dozens of customers in talks. Dassault also released Virtual Companions AURA, LEO and MARIE on its 3DEXPERIENCE platform. These AI tools aim to speed workflows and deepen customer lock-in.
Shows Dassault is monetizing AI across its key franchises, a potential driver of future growth.
Semiconductor digital twin partnership with Silvaco Silvaco and Dassault will link Silvaco's process simulation with Dassault's SIMULIA tools to create digital twin workflows for chip manufacturing. The partnership extends SIMULIA into semiconductor fabrication, a large new market, and could open additional revenue streams.
A new partnership that broadens Dassault's simulation reach into semiconductors, supporting long-term growth.

August 202616 Jul – 18 Aug 2026

▲4

Dassault expands life-sciences AI with ArisGlobal deal and new AI tools

ArisGlobal acquisition expands life-sciences AI platform Dassault agreed to buy ArisGlobal, a drug-safety and compliance software firm, for about $1.8 billion plus up to $200 million in milestone payments. ArisGlobal serves over 200 customers and half of the top 50 biopharma companies, deepening Dassault's life-sciences reach and adding recurring revenue.
This is the period's biggest strategic move, directly expanding a key growth business and supporting future revenue.
Q2 results solid, full-year targets confirmed Dassault reported Q2 revenue up 4% at constant currencies to €1.56 billion, with subscription revenue up 8% and cloud and 3DEXPERIENCE software each up 14%. Operating margin was 30.0% and earnings per share rose 8%. Management confirmed full-year targets, signaling steady demand.
Solid results and confirmed guidance underpin investor confidence in the company's core business.
New AI products launched across Medidata and 3DEXPERIENCE Medidata launched Medidata Plus, an AI layer for clinical trials, with dozens of customers in talks. Dassault also released Virtual Companions AURA, LEO and MARIE on its 3DEXPERIENCE platform. These AI tools aim to speed workflows and deepen customer lock-in.
Shows Dassault is monetizing AI across its key franchises, a potential driver of future growth.
Semiconductor digital twin partnership with Silvaco Silvaco and Dassault will link Silvaco's process simulation with Dassault's SIMULIA tools to create digital twin workflows for chip manufacturing. The partnership extends SIMULIA into semiconductor fabrication, a large new market, and could open additional revenue streams.
A new partnership that broadens Dassault's simulation reach into semiconductors, supporting long-term growth.

Latest16 Jul – 18 Aug 2026

▲4

Dassault expands life-sciences AI with ArisGlobal deal and new AI tools

ArisGlobal acquisition expands life-sciences AI platform Dassault agreed to buy ArisGlobal, a drug-safety and compliance software firm, for about $1.8 billion plus up to $200 million in milestone payments. ArisGlobal serves over 200 customers and half of the top 50 biopharma companies, deepening Dassault's life-sciences reach and adding recurring revenue.
This is the period's biggest strategic move, directly expanding a key growth business and supporting future revenue.
Q2 results solid, full-year targets confirmed Dassault reported Q2 revenue up 4% at constant currencies to €1.56 billion, with subscription revenue up 8% and cloud and 3DEXPERIENCE software each up 14%. Operating margin was 30.0% and earnings per share rose 8%. Management confirmed full-year targets, signaling steady demand.
Solid results and confirmed guidance underpin investor confidence in the company's core business.
New AI products launched across Medidata and 3DEXPERIENCE Medidata launched Medidata Plus, an AI layer for clinical trials, with dozens of customers in talks. Dassault also released Virtual Companions AURA, LEO and MARIE on its 3DEXPERIENCE platform. These AI tools aim to speed workflows and deepen customer lock-in.
Shows Dassault is monetizing AI across its key franchises, a potential driver of future growth.
Semiconductor digital twin partnership with Silvaco Silvaco and Dassault will link Silvaco's process simulation with Dassault's SIMULIA tools to create digital twin workflows for chip manufacturing. The partnership extends SIMULIA into semiconductor fabrication, a large new market, and could open additional revenue streams.
A new partnership that broadens Dassault's simulation reach into semiconductors, supporting long-term growth.

Manhattan Associates Inc (MANH)

Q3 202616 Jul – 27 Aug 2026

▲3▼1

Manhattan Associates Beats Q2, Raises 2026 Outlook; Legal Investigation Lingers

Q2 beat and raised 2026 guidance Manhattan Associates beat second-quarter estimates and raised its full-year 2026 revenue and adjusted earnings guidance. Cloud subscription revenue jumped 26%, and remaining performance obligations rose 23%, signaling strong future business. The stock jumped 11-25% on the news, as investors cheered the growth and outlook.
This is the main positive force behind the stock's recent move, directly driving the price up.
New Editions packaging expands market reach The company introduced a three-tier packaging strategy called Editions for its Manhattan Active solutions. This is a pricing and packaging change, not a new product, aimed at attracting more customers. It could broaden the addressable market and support future revenue growth, which is positive for the stock.
It explains a strategic move that could drive future demand and is part of the recent earnings announcement.
Share buybacks support stock Manhattan Associates repurchased about 874,000 shares for $125 million during the quarter, with $225 million remaining under its buyback program. Buybacks reduce the number of shares outstanding, which can boost earnings per share and support the stock price.
It highlights a capital return action that can positively influence the stock price.
Legal investigation into directors and officers Rosen Law Firm is investigating potential breaches of fiduciary duties by Manhattan Associates' directors and officers. While no lawsuit has been filed, the investigation could lead to legal action or governance changes, creating uncertainty that may weigh on the stock. This is a risk to watch.
It is a negative overhang that could pressure the stock, providing a fair counterweight to the positive news.

August 202616 Jul – 27 Aug 2026

▲3▼1

Manhattan Associates Beats Q2, Raises 2026 Outlook; Legal Investigation Lingers

Q2 beat and raised 2026 guidance Manhattan Associates beat second-quarter estimates and raised its full-year 2026 revenue and adjusted earnings guidance. Cloud subscription revenue jumped 26%, and remaining performance obligations rose 23%, signaling strong future business. The stock jumped 11-25% on the news, as investors cheered the growth and outlook.
This is the main positive force behind the stock's recent move, directly driving the price up.
New Editions packaging expands market reach The company introduced a three-tier packaging strategy called Editions for its Manhattan Active solutions. This is a pricing and packaging change, not a new product, aimed at attracting more customers. It could broaden the addressable market and support future revenue growth, which is positive for the stock.
It explains a strategic move that could drive future demand and is part of the recent earnings announcement.
Share buybacks support stock Manhattan Associates repurchased about 874,000 shares for $125 million during the quarter, with $225 million remaining under its buyback program. Buybacks reduce the number of shares outstanding, which can boost earnings per share and support the stock price.
It highlights a capital return action that can positively influence the stock price.
Legal investigation into directors and officers Rosen Law Firm is investigating potential breaches of fiduciary duties by Manhattan Associates' directors and officers. While no lawsuit has been filed, the investigation could lead to legal action or governance changes, creating uncertainty that may weigh on the stock. This is a risk to watch.
It is a negative overhang that could pressure the stock, providing a fair counterweight to the positive news.

Latest16 Jul – 27 Aug 2026

▲3▼1

Manhattan Associates Beats Q2, Raises 2026 Outlook; Legal Investigation Lingers

Q2 beat and raised 2026 guidance Manhattan Associates beat second-quarter estimates and raised its full-year 2026 revenue and adjusted earnings guidance. Cloud subscription revenue jumped 26%, and remaining performance obligations rose 23%, signaling strong future business. The stock jumped 11-25% on the news, as investors cheered the growth and outlook.
This is the main positive force behind the stock's recent move, directly driving the price up.
New Editions packaging expands market reach The company introduced a three-tier packaging strategy called Editions for its Manhattan Active solutions. This is a pricing and packaging change, not a new product, aimed at attracting more customers. It could broaden the addressable market and support future revenue growth, which is positive for the stock.
It explains a strategic move that could drive future demand and is part of the recent earnings announcement.
Share buybacks support stock Manhattan Associates repurchased about 874,000 shares for $125 million during the quarter, with $225 million remaining under its buyback program. Buybacks reduce the number of shares outstanding, which can boost earnings per share and support the stock price.
It highlights a capital return action that can positively influence the stock price.
Legal investigation into directors and officers Rosen Law Firm is investigating potential breaches of fiduciary duties by Manhattan Associates' directors and officers. While no lawsuit has been filed, the investigation could lead to legal action or governance changes, creating uncertainty that may weigh on the stock. This is a risk to watch.
It is a negative overhang that could pressure the stock, providing a fair counterweight to the positive news.